Author: Rich Meyers

Market conditions are straightforward this week. We could add fluff for the sake of running up word counts but will just stick to the facts as we see them. If stocks can’t find their way north after seven consecutive down...

Everybody loves a good sale. Corporate insiders picked up their buying activity as stocks got cracked last week. Last week’s list of buyers was noticeably longer than it’s been for the past month. Growing insider interest doesn’t necessarily mean the...

It was a not so Manic Monday, to paraphrase The Bangles’ 1986 hit song. The S&P 500 and Dow spent much of the afternoon in the plus column before stumbling at the bell. Meanwhile, the NASDAQ was red all day...

The market continues to be in a perilous situation, flirting with potentially waterfalling lower. It might not take too much of a push to initiate outsized losses. With the possibility of a crash, we will stick with the theme we’ve...

When you are caught in the rain, you don’t need a meteorologist’s weather forecast. Afterall, you are soaking wet. When the NASDAQ crashes more than 4% in a day, you don’t need a stock prognosticator to tell you the market...

Last week we talked about identifying industry leaders that are getting trashed as the market falls, especially those with insider buying. We are going to continue with that theme this week. The idea is to compile a list of quality...

Bulls won a tug of war with bears to start the week. The NASDAQ was up early in the session before falling to make a new 52-week, intraday low and closed well into the green by day’s end. Investors might...

To be honest, there isn’t anything on last week’s insider buying roster that made the cut for us. Inozyme Pharma, Inc. (INZY), a startup biotech came close, but the company is a long way from profitability and an approved product....